
Evidence analysis
Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study
Risk of Cardiovascular Events and Mortality Associated with LDL and Non-HDL Cholesterol Levels After Statin Initiation for Primary Prevention: A Multiregional Cohort Study This article examines recent research published in PLOS Medicine analyzing the associations between cholesterol levels…
Read →
Evidence analysis
Transforming pandemic influenza antiviral stockpiling using a capacity-based approach: A modeling study
Transforming Pandemic Influenza Antiviral Stockpiling: A Capacity-Based Model Assessment Source: PLOS Medicine, November 3, 2026 What is Established Global preparedness for pandemic influenza has historically relied on maintaining large antiviral drug stockpiles, with coverage targets often set at…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Bildyos, denosumab, Date of authorisation: 17/09/2025, Revision: 5, Status: Authorised
What is established Bildyos is a biosimilar medicine containing the active substance denosumab, authorized for use in the European Union as of September 17, 2025. It is approved to treat osteoporosis in postmenopausal women and in men with…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Vlustozik (previously Ibuprofen Gen.Orph), ibuprofen, Date of authorisation: 16/02/2024, Revision: 5, Status: Authorised
What is established The European Medicines Agency (EMA) authorized the use of Vlustozik, a generic injectable ibuprofen medicine, on February 16, 2024. This medicine is indicated for treating patent ductus arteriosus (PDA) in premature newborns born before 34…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Veanibek (previously Miglustat Gen.Orph), miglustat, Date of authorisation: 09/11/2017, Revision: 13, Status: Authorised
What is established Miglustat is a medicine used in the treatment of rare inherited diseases characterized by the build-up of certain fatty substances called glycosphingolipids. Specifically, it is indicated for adults with mild to moderate type-1 Gaucher disease…
Read →
Evidence analysis
Trends in the incidence of childhood type 1 diabetes after the COVID-19 lockdown in Finland: An observational study
Trends in Childhood Type 1 Diabetes Incidence in Finland After COVID-19 Lockdown: Evidence Overview A recent observational study published in PLOS Medicine investigates how the incidence of childhood type 1 diabetes (T1D) in Finland evolved following the COVID-19…
Read →
Evidence analysis
Addressing threats to validity in large dataset research
Addressing Validity Threats in Large Dataset Biomedical Research: An Evidence-Based Overview In the era of big data, biomedical research increasingly leverages massive integrated datasets combining clinical, genomic, environmental, and social information. While these datasets enable analyses of complex…
Read →
Evidence analysis
Disillusion runs deep among young Americans
Disillusionment Among Young Americans: An Evidence Dossier What is Established Recent polling data reveals significant disillusionment among young Americans, particularly those aged 18 to 29, regarding their economic prospects and the health of American democracy. The Harvard Kennedy…
Read →
Evidence analysis
About half of drinkers on GLP-1s say they imbibed less
What is established Glucagon-like peptide-1 receptor agonists (GLP-1s) are medications primarily prescribed for treating type 2 diabetes and obesity. These drugs have gained substantial popularity due to their weight loss efficacy. Historical evidence confirms that medications exist to…
Read →
Evidence analysis
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 – 29 October 2026
Pharmacovigilance Update: PRAC Reviews on Deanxit and Human Normal Immunoglobulin Medicines – October 2026 This evidence dossier summarizes key findings and ongoing assessments from the Pharmacovigilance Risk Assessment Committee (PRAC) meeting held from 26 to 29 October 2026,…
Read →